| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 01/23/2003 | WO2001083782A3 Novel proteases |
| 01/23/2003 | WO2001051472A9 New imidazole derivatives |
| 01/23/2003 | US20030018194 New Vitamin D derivatives with cyclopropyl rings in the side chains, process and intermediate products for their production and their use for the production of pharmaceutical agents |
| 01/23/2003 | US20030018189 Cyclic polyamines having total 9-24 members which have activity in against HIV-infected cells as well as other biological activity related to binding of ligands to chemokine receptors |
| 01/23/2003 | US20030018180 Secreted protein HFEAF41 |
| 01/23/2003 | US20030018083 Methods of treating and preventing pain, anxiety, and incontinence using derivatives of (-)-venlafaxine |
| 01/23/2003 | US20030018080 N-methoxymethyl-5,5-diphenylbarbituric acid |
| 01/23/2003 | US20030018067 Cardiovascular disorders; anticancer agents |
| 01/23/2003 | US20030018064 Substituted benzofurans and benzothiophenes, methods of making and methods of use as integrin antagonists |
| 01/23/2003 | US20030018060 Therapeutic methods and compositions involving isoflavones |
| 01/23/2003 | US20030018053 Substituted indolealkanoic acids |
| 01/23/2003 | US20030018043 N-methylnalorphine |
| 01/23/2003 | US20030018041 Spiroindene and spiroindane compounds |
| 01/23/2003 | US20030018040 Tumor necrosis factor antagonist; side effect reduction;antiinflammatory agents |
| 01/23/2003 | US20030018038 1,4 substituted piperidinyl NMDA/NR2B antagonists |
| 01/23/2003 | US20030018035 Central nervous system disorders |
| 01/23/2003 | US20030018032 Bicyclic imidazo-3-yl-amine derivatives |
| 01/23/2003 | US20030018030 Antiepileptic agents |
| 01/23/2003 | US20030018027 Methods and pharmaceutical compositions for preventing problem behaviors of companion animals |
| 01/23/2003 | US20030018026 Preterm labor; urogenital disorders; fertility; psychological disorders |
| 01/23/2003 | US20030018021 Piperidine derivatives as subtype selective N-methyl-D-aspartate antagonists |
| 01/23/2003 | US20030018013 Cardiovascular disorders; antilipemic agents; Alzheimer's disease |
| 01/23/2003 | US20030018008 Synergistic mixture of adenosine antagonist and antiserotonine agent |
| 01/23/2003 | US20030017991 Substrates and assays for beta-secretase activity |
| 01/23/2003 | US20030017966 MC4-R as target for the identification of compounds used to treat drug addiction |
| 01/23/2003 | US20030017965 Methods for treating certain diseases using naaladase inhibitors |
| 01/23/2003 | US20030017617 Mammalian receptor proteins; related reagents and methods |
| 01/23/2003 | US20030017533 Slo2 and Slo4, novel potassium channel proteins from human brain |
| 01/23/2003 | US20030017527 Human vanilloid receptor-like proteins |
| 01/23/2003 | US20030017479 Methods for the detection, treatment, and prevention of neurodegeneration |
| 01/23/2003 | US20030017220 Process for the extraction of valerian root |
| 01/23/2003 | US20030017201 Pharmaceutical composition comprising entracapone, levodopa, and carbidopa |
| 01/23/2003 | US20030017166 Combination preparation for the therapy of immunological diseases |
| 01/23/2003 | US20030017145 Treating subjects suffering from herpes virus infections, acquired immunodeficiency syndrome, and hepatitis C infections by administering a compound effective to inhibit the production or release of the ROMs. |
| 01/23/2003 | US20030017141 Treatment of conditions characterized by a need to modulate migratory-cell movement associated with specific sites in a subject; isolating a stromal-cell-derived fugetactic agent |
| 01/23/2003 | US20030017120 Delivery of erectile dysfunction drugs through an inhalation route |
| 01/23/2003 | US20030017119 Aerosol comprises particles comprising at least 10 percent by weight of an opioid, and wherein the opioid is not heroin; opiods include morphine, codeine, naltrexone, buprenorphine, fentanyl, nalbuphine, naloxone, etc. |
| 01/23/2003 | US20030017118 An aerosol for inhalation therapy, wherein the aerosol comprises particles comprising at least 10 percent by weight of an antipsychotic such as olanzapine, trifluoperazine, haloperidol, loxapine, clozapine, quetiapine, promazine, etc. |
| 01/23/2003 | US20030017117 Delivery of analgesics through an inhalation route |
| 01/23/2003 | US20030017116 Delivery of sedative-hypnotics through an inhalation route |
| 01/23/2003 | US20030017115 Aerosol comprises particles comprising at least 10 percent by weight of a drug ester. |
| 01/23/2003 | US20030017114 Aerosol comprises particles of chlordiazepoxide, betahistine, clonidine, testosterone, conjugated estrogens, estrogen esters, estradiol, estradiol esters, ethinyl estradiol, ethinyl estradiol esters, or hyoscyamine. |
| 01/23/2003 | US20030015190 Delivery of compounds for the treatment of migraine through an inhalation route |
| 01/23/2003 | US20030015189 Delivery of antihistamines through an inhalation route |
| 01/23/2003 | CA2453554A1 Heteroaryl substituted fused bicyclic heteroaryl compounds as gabaa receptor ligands |
| 01/23/2003 | CA2453503A1 N-(3-amino-2-hydroxy-propyl) substituted alkylamide compounds |
| 01/23/2003 | CA2453451A1 Aminediols for the treatment of alzheimer's disease |
| 01/23/2003 | CA2453447A1 Alpha-hydroxyamide statine derivatives for the treatment of alzheimer's disease |
| 01/23/2003 | CA2453444A1 Diaminediols for the treatment of alzheimer's disease |
| 01/23/2003 | CA2453403A1 Methods of inhibiting amyloid toxicity |
| 01/23/2003 | CA2453399A1 Combinations for the treatment of inflammatory disorders |
| 01/23/2003 | CA2453389A1 Aerosol formulations of .delta.8 tetrahydrocannabinol |
| 01/23/2003 | CA2453362A1 Oligonucleotide-containing pharmacological compositions and their use |
| 01/23/2003 | CA2453183A1 In vivo production of small interfering rnas that mediate gene silencing |
| 01/23/2003 | CA2453175A1 Interaction inhibitors of tcf-4 with beta-catenin |
| 01/23/2003 | CA2453159A1 A composition and uses therefor for combating hangover |
| 01/23/2003 | CA2453147A1 Methods of treating cytokine mediated diseases |
| 01/23/2003 | CA2452612A1 Novel anticonvulsant derivative salts |
| 01/23/2003 | CA2452610A1 Hexahydroazepino (4, 5-g) indoles and indolines as 5-ht receptor ligands |
| 01/23/2003 | CA2452544A1 Method for treating secondary tissue degeneration associated with central nervous system injury |
| 01/23/2003 | CA2452513A1 Amide-containing compound having improved solubility and method of improving the solubility of an amide-containing compound |
| 01/23/2003 | CA2451569A1 Carbocyclic hydrazino inhibitors of copper-containing amine oxidases |
| 01/23/2003 | CA2451566A1 Use of nk-1 receptor antagonists for the treatment of brain, spinal or nerve injury |
| 01/23/2003 | CA2448558A1 Drug delivery system for zero order, zero order-biphasic, ascending or descending drug delivery |
| 01/23/2003 | CA2448553A1 A pharmaceutical composition comprising a nicotinic receptor partial antagonist and an antiemetic agent of modulating cholinergic function |
| 01/23/2003 | CA2446726A1 Piperazine oxime derivatives having nk-1 receptor antagonistic activity |
| 01/23/2003 | CA2417156A1 3,4-dihydroisoquinoline derivative compound and a pharmaceutical agent comprising it as active ingredient |
| 01/22/2003 | EP1277746A2 N-benzylpiperazine derivatives, process for their preparation and pharmaceutical compositions thereof |
| 01/22/2003 | EP1277743A1 Oxa(thia)zolidine derivative and anti-inflammatory drug |
| 01/22/2003 | EP1277737A1 Diphenylalkylamine derivatives useful as opioid delta receptor agonists |
| 01/22/2003 | EP1277736A1 Novel bicyclic compounds |
| 01/22/2003 | EP1277729A1 Ppar (gamma) modulators |
| 01/22/2003 | EP1277478A1 Medicinal compositions for suppressing beta-amyloid production |
| 01/22/2003 | EP1277477A2 Treatment of neurodegenerative diseases and the effects of aging |
| 01/22/2003 | EP1277473A1 Remedies |
| 01/22/2003 | EP1277468A1 Compositions for promoting sleep |
| 01/22/2003 | EP1276893A1 Purified and isolated potassium-chloride cotransporter nucleic acids and polypeptides and therapeutic and screening methods using same |
| 01/22/2003 | EP1276880A2 Polymorphisms in the human cyp2d6 gene promoter region and their use in diagnostic and therapeutic applications |
| 01/22/2003 | EP1276878A2 Reversible immortalization |
| 01/22/2003 | EP1276872A2 A thymus expressed human cytochrome p450 (p450tec) |
| 01/22/2003 | EP1276867A2 Regulation of human latrophilin-like g protein-coupled receptor |
| 01/22/2003 | EP1276856A1 Albumin fusion proteins |
| 01/22/2003 | EP1276849A2 Albumin fusion proteins |
| 01/22/2003 | EP1276764A1 Human polynucleotides, polypeptides, and antibodies |
| 01/22/2003 | EP1276761A2 New bromodomain protein |
| 01/22/2003 | EP1276755A1 Novel compounds |
| 01/22/2003 | EP1276738A1 2-amino-3-(alkyl)-pyrimidone derivatives as gsk3.beta. inhibitors |
| 01/22/2003 | EP1276731A2 Branched adamantyl and noradamantyl aryl- and aralkylpiperazines with serotonin 5-ht 1a activity |
| 01/22/2003 | EP1276729A1 New neurokinin antagonists for use as medicaments |
| 01/22/2003 | EP1276728A2 Ultrashort acting hypnotic barbiturates |
| 01/22/2003 | EP1276727A1 Novel amino carboxy alkyl derivatives of barbituric acid |
| 01/22/2003 | EP1276714A2 Cyclic carboxylic acids as integrin antagonists |
| 01/22/2003 | EP1276494A1 A memory enhancing protein |
| 01/22/2003 | EP1276487A1 Treatment of conditions of the central nervous system using mycobacteria |
| 01/22/2003 | EP1276483A2 Compositions and methods for treating amyloidosis using sulphonate derivatives |
| 01/22/2003 | EP1276478A2 (2-aminoethyl) oxime derivatives for the treatment of depression |
| 01/22/2003 | EP1276475A2 Topical anesthetic/opioid formulations and uses thereof |
| 01/22/2003 | EP1165537B1 Hydroxymatairesinol in cancer prevention |
| 01/22/2003 | EP1107738A4 Novel pharmaceutical salt form |
| 01/22/2003 | EP1030835B1 Urea derivatives and their use as integrin inhibitors |